Multicenter Registry Study of Patients With Intracranial Dural Arteriovenous Fistulas in China (DREAM)
May 18, 2026 updated by: Xuanwu Hospital, Beijing
Dural Arteriovenous Fistulas Registry, Evaluation, and Management Study in China (DREAM)
This multicenter registry study aims to clarify the incidence trends of intracranial dural arteriovenous fistulas (IDAVF) and spinal dural arteriovenous fistulas (SDAVF) in China, evaluate current treatment patterns, and establish a nationwide multicenter retrospective and prospective database.
The study is designed as a multicenter retrospective and prospective observational study involving more than 60 core hospitals across seven major geographic regions of China.
The retrospective phase will include patients diagnosed between February 28, 2015 and February 28, 2025, while the prospective phase will enroll patients from March 1, 2025 to March 1, 2030.
Eligible participants are patients diagnosed with IDAVF or SDAVF by digital subtraction angiography (DSA).
The study will analyze disease incidence and temporal trends, collect baseline demographic and clinical characteristics, and evaluate treatment outcomes including obliteration rate, recurrence rate, and clinical prognosis.
The crude incidence rate per 100,000 person-years during the study period will also be calculated based on Chinese census population data.
The primary endpoint is the improvement rate in modified Rankin Scale (mRS) score at 6 months after treatment.
Secondary endpoints include obliteration and recurrence rates on imaging follow-up at 6 months and improvement in mRS score at 12 months after treatment.
Statistical analyses will be performed using SAS 9.4 software, including descriptive analyses as well as univariate and multivariate regression analyses to identify factors associated with clinical outcomes and prognosis.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
10050
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xin Su, M.D
- Phone Number: 86-18210685023
- Email: 1258940078@qq.com
Study Contact Backup
- Name: Yongjie Ma, M.D
- Email: 1258940078@qq.com
Study Locations
-
-
-
Beijing, China, 100053
- Xuanwu Hospital
-
Contact:
- Peng Zhang
- Phone Number: 86-13911029232
- Email: 1258940078@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The study population consists of patients diagnosed with intracranial dural arteriovenous fistulas (IDAVF) or spinal dural arteriovenous fistulas (SDAVF) at more than 60 participating centers across seven geographic regions of China.
Both retrospective and prospective cohorts will be included.
Eligible patients will be identified based on digital subtraction angiography (DSA)-confirmed diagnosis and available clinical and imaging data.
Description
Inclusion Criteria:
- Patients diagnosed with intracranial dural arteriovenous fistula (IDAVF) or spinal dural arteriovenous fistula (SDAVF) by cerebral or spinal digital subtraction angiography (DSA)
- Patients treated or evaluated at participating centers during the study period
- Availability of complete clinical and imaging records, including baseline information, treatment records, and DSA images
- For the prospective cohort, written informed consent signed by the patient or legal representative
Exclusion Criteria:
- Patients with facial or scalp arteriovenous fistulas
- Patients with non-dural vascular malformations or non-arteriovenous fistula vascular diseases, including cavernous malformations or venous malformations
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improvement in modified Rankin Scale (mRS) score at 6 months after treatment
Time Frame: 6 months after treatment
|
The primary outcome measure is the proportion of patients demonstrating improvement in neurological functional status, as assessed by the modified Rankin Scale (mRS), at 6 months after treatment.
Clinical outcomes will be evaluated through outpatient or telephone follow-up.
|
6 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Angiographic obliteration and recurrence rates at 6 months after treatment
Time Frame: 6 months after treatment
|
The secondary outcome measure includes angiographic obliteration and recurrence rates of intracranial or spinal dural arteriovenous fistulas at 6 months after treatment, as assessed by follow-up DSA, CTA, or MRA when available.
|
6 months after treatment
|
|
Improvement in modified Rankin Scale (mRS) score at 12 months after treatment
Time Frame: 12 months after treatment
|
The secondary outcome measure is the proportion of patients demonstrating improvement in neurological functional status, as assessed by the modified Rankin Scale (mRS), at 12 months after treatment.
Clinical outcomes will be evaluated through outpatient or telephone follow-up.
|
12 months after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 18, 2026
Primary Completion (Estimated)
February 28, 2030
Study Completion (Estimated)
February 28, 2030
Study Registration Dates
First Submitted
May 18, 2026
First Submitted That Met QC Criteria
May 18, 2026
First Posted (Actual)
May 22, 2026
Study Record Updates
Last Update Posted (Actual)
May 22, 2026
Last Update Submitted That Met QC Criteria
May 18, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- zpmyjsx930826
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracranial Dural Arteriovenous Fistula
-
Thomas Jefferson UniversityRecruitingSpinal Dural Arteriovenous FistulaUnited States
-
Dr. Markus Alfred MöhlenbruchUniversity Hospital Schleswig-HolsteinCompletedDural Arteriovenous FistulaGermany
-
Microvention-Terumo, Inc.ClinSearchCompletedDural Arteriovenous FistulaUnited Kingdom, Spain, Denmark, France, Sweden
-
Microvention-Terumo, Inc.Completed
-
Keuro MedTechCompletedAcute Ischemic Stroke | Intracranial Aneurysm | AV Fistula | Extracranial Atherosclerosis | AVM - Cerebral Arteriovenous MalformationChina
-
Medtronic Neurovascular Clinical AffairsCompletedArteriovenous FistulaFrance
-
Dynamic LightBarrow Neurological InstituteCompletedAneurysm, AVM, Dural Arteriovenous Fistula, Glioma, Meningioma, Metastasis, BypassUnited States
-
University Hospital Inselspital, BerneCompletedGlioma | Aneurysm | Metastasis | Meningioma | AVM | Dural Arteriovenous FistulaSwitzerland
-
Hongqi Zhang, MDBeijing Haidian HospitalRecruitingSpinal Vascular Disorder NosChina
Clinical Trials on endovascular
-
Cook Research IncorporatedCompleted
-
Aswan UniversityCompletedCritical Limb Ischemia | Tibialis Vessels OcclusionEgypt
-
Cook Research IncorporatedApproved for marketingAortic DissectionUnited States
-
William Cook EuropeCook Group Incorporated; MED Institute, Incorporated; William Cook AustraliaCompletedAortic Dissection Involving the Descending Thoracic AortaItaly, Germany, Australia, Czech Republic, France
-
Stanford UniversityEnrolling by invitationStroke, Acute | Ischemic Stroke, AcuteUnited States
-
Inovatyvi Medicina UABKCRI; Syntropic Corelab; SIA KotelloCompletedAny Disease Which Requires Peripheral Endovascular InterventionLatvia
-
liuxingjuBeijing Municipal Science & Technology CommissionUnknownIntracranial Aneurysm | Atheroscleroses, Cerebral | Cerebrovascular StenosisChina
-
Cook Research IncorporatedCompleted
-
Cook Group IncorporatedCompleted
-
Cook Group IncorporatedCompleted